Oxidation-specific biomarkers and risk of peripheral artery disease

Journal of the American College of Cardiology

Volumn 61, Issue 21, 2013, Pages 2169-2179

  Bertoia, Monica L ^a,b   Pai, Jennifer K ^b,c   Lee, Jun Hee ^d,e   Taleb, Adam ^d   Joosten, Michel M ^a,b,f,g   Mittleman, Murray A ^a,b   Yang, Xiaohong ^d   Witztum, Joseph L ^d   Rimm, Eric B ^b,c   Tsimikas, Sotirios ^d   Mukamal, Kenneth J ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e Hallym University Medical Center   (South Korea)

^f TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

autoantibodies; biomarker; immune complex; lipoprotein (a); oxidized phospholipids; peripheral artery disease

Indexed keywords

APOLIPOPROTEIN B100; AUTOANTIBODY; BIOLOGICAL MARKER; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; OXIDIZED PHOSPHOLIPID; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; SMOKING;

ADULT; AGED; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOPROTEIN(A); LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PERIPHERAL ARTERIAL DISEASE; PHOSPHOLIPIDS; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84877987644     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.02.047     Document Type: Article

References (50)

1. M.H. Criqui Peripheral arterial disease - epidemiological aspects Vasc Med 6 Suppl 2001 3 7
2. Y. Ostchega, R. Paulose-Ram, C.F. Dillon, Q. Gu, J.P. Hughes Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004 J Am Geriatr Soc 55 2007 583 589
3. A.T. Hirsch, Z.J. Haskal, N.R. Hertzer ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) Circulation 113 2006 e463 e654
4. M.M. McDermott, K. Liu, P. Greenland Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms JAMA 292 2004 453 461
5. J.A. Berliner, M. Navab, A.M. Fogelman Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics Circulation 91 1995 2488 2496
6. M. Navab, S.S. Imes, S.Y. Hama Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein J Clin Invest 88 1991 2039 2046
7. A. Taleb, J.L. Witztum, S. Tsimikas Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events Biomarkers Med 5 2011 673 694
8. C. Bergmark, A. Dewan, A. Orsoni A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma J Lipid Res 49 2008 2230 2239
9. J.A. Berliner, N. Leitinger, S. Tsimikas The role of oxidized phospholipids in atherosclerosis J Lipid Res 50 Suppl 2009 S207 S212
10. V.N. Bochkov, O.V. Oskolkova, K.G. Birukov, A.L. Levonen, C.J. Binder, J. Stockl Generation and biological activities of oxidized phospholipids Antioxid Redox Signal 12 2010 1009 1059
11. Y.I. Miller, S.H. Choi, P. Wiesner Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity Circ Res 108 2011 235 248
12. D. Weismann, K. Hartvigsen, N. Lauer Complement factor H binds malondialdehyde epitopes and protects from oxidative stress Nature 478 2011 76 81
13. S. Tsimikas, S. Kiechl, J. Willeit Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study J Am Coll Cardiol 47 2006 2219 2228
14. J. Hulthe, L. Bokemark, B. Fagerberg Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men Arterioscler Thromb Vasc Biol 21 2001 101 107
15. J. Karvonen, M. Paivansalo, Y.A. Kesaniemi, S. Horkko Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis Circulation 108 2003 2107 2112
16. C. Bergmark, R. Wu, U. de Faire, A.K. Lefvert, J. Swedenborg Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL Arterioscler Thromb Vasc Biol 15 1995 441 445
17. S. Tsimikas, H.K. Lau, K.R. Han Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein Circulation 109 2004 3164 3170
18. S. Tsimikas, J.L. Witztum, E.R. Miller High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial Circulation 110 2004 1406 1412
19. M.M. Joosten, J.K. Pai, M.L. Bertoia Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men JAMA 308 2012 1660 1667
20. S. Chasan-Taber, E.B. Rimm, M.J. Stampfer Reproducibility and validity of a self-administered physical activity questionnaire for male health professionals Epidemiology 7 1996 81 86
21. E.B. Rimm, M.J. Stampfer, G.A. Colditz, C.G. Chute, L.B. Litin, W.C. Willett Validity of self-reported waist and hip circumferences in men and women Epidemiology 1 1990 466 473
22. A.M. Wolf, D.J. Hunter, G.A. Colditz Reproducibility and validity of a self-administered physical activity questionnaire Int J Epidemiol 23 1994 991 999
23. C. Lahoute, O. Herbin, Z. Mallat, A. Tedgui Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets Nat Rev Cardiol 8 2011 348 358
24. J.P. Cooke, A.M. Wilson Biomarkers of peripheral arterial disease J Am Coll Cardiol 55 2010 2017 2023
25. S. Tsimikas, P. Willeit, J. Willeit Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net re-classification of cardiovascular events J Am Coll Cardiol 60 2012 2218 2229
26. S. Tsimikas, Z. Mallat, P.J. Talmud Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events J Am Coll Cardiol 56 2010 946 955
27. S. Kiechl, J. Willeit, M. Mayr Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study Arterioscler Thromb Vasc Biol 27 2007 1788 1795
28. S. Tsimikas, P. Clopton, E.S. Brilakis Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study Circulation 119 2009 1711 1719
29. S. Volpato, G.B. Vigna, M.M. McDermott Lipoprotein(a), inflammation, and peripheral arterial disease in a community-based sample of older men and women (the InCHIANTI study) Am J Cardiol 105 2010 1825 1830
30. A.D. Pradhan, S. Shrivastava, N.R. Cook, N. Rifai, M.A. Creager, P.M. Ridker Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk Circulation 117 2008 823 831
31. G.T. Jones, A.M. van Rij, J. Cole Plasma lipoprotein(a) indicates risk for 4 distinct forms of vascular disease Clin Chem 53 2007 679 685
32. B. Dieplinger, A. Lingenhel, N. Baumgartner Increased serum lipoprotein(a) concentrations and low molecular weight phenotypes of apolipoprotein(a) are associated with symptomatic peripheral arterial disease Clin Chem 53 2007 1298 1305
33. M.D. Widmann, B.E. Sumpio Lipoprotein (a): a risk factor for peripheral vascular disease Ann Vasc Surg 7 1993 446 451
34. C.H. Tseng Lipoprotein(a) is an independent risk factor for peripheral arterial disease in Chinese type 2 diabetic patients in Taiwan Diabetes Care 27 2004 517 521
35. J. Tyrrell, T. Cooke, M. Reilly Lipoprotein [Lp(a)] and peripheral vascular disease J Intern Med 232 1992 349 352
36. D. Gurdasani, B. Sjouke, S. Tsimikas Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: The EPIC-Norfolk Prospective Population Study Arterioscler Thromb Vasc Biol 32 2012 3058 3065
37. J.H. Ix, M.A. Allison, J.O. Denenberg, M. Cushman, M.H. Criqui Novel cardiovascular risk factors do not completely explain the higher prevalence of peripheral arterial disease among African Americans. The San Diego Population Study J Am Coll Cardiol 51 2008 2347 2354
38. P.M. Ridker, M.J. Stampfer, N. Rifai Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease JAMA 285 2001 2481 2485
39. V. Aboyans, M.H. Criqui, J.O. Denenberg, J.D. Knoke, P.M. Ridker, A. Fronek Risk factors for progression of peripheral arterial disease in large and small vessels Circulation 113 2006 2623 2629
40. J.B. Dube, M.B. Boffa, R.A. Hegele, M.L. Koschinsky Lipoprotein(a): more interesting than ever after 50 years Curr Opin Lipidol 23 2012 133 140
41. S. Erqou, S. Kaptoge, P.L. Perry Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality JAMA 302 2009 412 423
42. J.D. Spence, M. Koschinsky Mechanisms of lipoprotein(a) pathogenicity: prothrombotic, proatherosclerotic, or both? Arterioscler Thromb Vasc Biol 32 2012 1550 1551
43. T.A. Seimon, M.J. Nadolski, X. Liao Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress Cell Metab 12 2010 467 482
44. M. Mayr, S. Kiechl, S. Tsimikas Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study J Am Coll Cardiol 47 2006 2436 2443
45. S. Tsimikas, C. Bergmark, R.W. Beyer Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes J Am Coll Cardiol 41 2003 360 370
46. R. Wu, U. de Faire, C. Lemne, J.L. Witztum, J. Frostegard Autoantibodies to OxLDL are decreased in individuals with borderline hypertension Hypertension 33 1999 53 59
47. M. Puurunen, M. Manttari, V. Manninen Antibody against oxidized low-density lipoprotein predicting myocardial infarction Arch Intern Med 154 1994 2605 2609
48. A.T. Erkkila, O. Narvanen, S. Lehto, M.I. Uusitupa, S. Yla-Herttuala Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease Arterioscler Thromb Vasc Biol 20 2000 204 209
49. A. Mustafa, S. Nityanand, L. Berglund, H. Lithell, A.K. Lefvert Circulating immune complexes in 50-year-old men as a strong and independent risk factor for myocardial infarction Circulation 102 2000 2576 2581
50. S.S. Virani, A. Brautbar, B.C. Davis Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study Circulation 125 2012 241 249